ScoreWhy is Sudarshan Pharma Industries Ltd ?
1
Healthy long term growth as Operating profit has grown by an annual rate 47.89%
2
Positive results in Mar 26
- PBT LESS OI(Q) At Rs 11.57 cr has Grown at 120.9% (vs previous 4Q average)
- NET SALES(Q) Highest at Rs 220.92 cr
- PBDIT(Q) Highest at Rs 20.19 cr.
3
With ROCE of 10.5, it has a Attractive valuation with a 2.6 Enterprise value to Capital Employed
- Over the past year, while the stock has generated a return of 16.87%, its profits have risen by 36% ; the PEG ratio of the company is 1.1
4
Market Beating performance in long term as well as near term
- Along with generating 16.87% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Sudarshan Pharma should be less than 10%
- Overall Portfolio exposure to Specialty Chemicals should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Specialty Chemicals)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Sudarshan Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Sudarshan Pharma
16.87%
0.31
54.34%
Sensex
-8.4%
-0.65
12.97%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
28.10%
EBIT Growth (5y)
47.89%
EBIT to Interest (avg)
2.37
Debt to EBITDA (avg)
5.40
Net Debt to Equity (avg)
1.85
Sales to Capital Employed (avg)
1.53
Tax Ratio
23.33%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
20.00%
ROCE (avg)
10.59%
ROE (avg)
13.36%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
36
Industry P/E
34
Price to Book Value
5.52
EV to EBIT
24.71
EV to EBITDA
22.99
EV to Capital Employed
2.59
EV to Sales
1.69
PEG Ratio
1.06
Dividend Yield
NA
ROCE (Latest)
10.47%
ROE (Latest)
14.39%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend20What is working for the Company
PBT LESS OI(Q)
At Rs 11.57 cr has Grown at 120.9% (vs previous 4Q average
NET SALES(Q)
Highest at Rs 220.92 cr
PBDIT(Q)
Highest at Rs 20.19 cr.
PAT(Q)
Highest at Rs 10.73 cr.
EPS(Q)
Highest at Rs 0.45
-3What is not working for the Company
INTEREST(Q)
Highest at Rs 7.53 cr
Loading Valuation Snapshot...
Here's what is working for Sudarshan Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 11.57 cr has Grown at 120.9% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 5.24 CrMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 10.73 cr has Grown at 102.2% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 5.31 CrMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 220.92 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 220.92 cr has Grown at 37.3% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 160.93 CrMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 20.19 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 11.57 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 10.73 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 0.45
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Sudarshan Pharma
Interest - Quarterly
Highest at Rs 7.53 cr
in the last five quarters and Increased by 19.90 % (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
Non Operating Income - Quarterly
Highest at Rs 4.13 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
